[Federal Register Volume 86, Number 49 (Tuesday, March 16, 2021)]
[Notices]
[Pages 14447-14448]
[FR Doc No: 2021-05368]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-N-0212]

Bristol-Meyers Squibb Company, et al.; Withdrawal of Approval of
19 New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is
withdrawing approval of 19 new drug applications (NDAs) from multiple
applicants. The applicants notified the Agency in writing that the drug
products were no longer marketed and requested that the approval of the
applications be withdrawn.

DATES: Approval is withdrawn as of April 15, 2021.

FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-
796-3137<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The applicants listed in the table have
informed FDA that these drug products are no longer marketed and have
requested that FDA withdraw approval of the applications under the
process in Sec.  314.150(c) (21 CFR 314.150(c)). The applicants have
also, by their requests, waived their opportunity for a hearing.
Withdrawal of approval of an application or abbreviated application
under Sec.  314.150(c) is without prejudice to refiling.

------------------------------------------------------------------------
    Application No.                Drug                  Applicant
------------------------------------------------------------------------
NDA 009218.............  Coumadin (warfarin       Bristol-Myers Squibb
                          sodium) Tablets, 1       Co., P.O. Box 4000,
                          milligram (mg), 2 mg,    Princeton, NJ 08543.
                          2.5 mg, 3 mg, 4 mg, 5
                          mg, 6 mg, 7.5 mg, and
                          10 mg.
                         Coumadin (warfarin
                          sodium) Injection, 5
                          mg/vial, 50 mg/vial,
                          and 75 mg/vial.
NDA 011664.............  Decadron                 Merck Sharp & Dohme
                          (dexamethasone)          Corp., a subsidiary
                          Tablets, 0.25 mg, 0.5    of Merck & Co., Inc.,
                          mg, 0.75 mg, 1.5 mg, 4   1 Merck Dr.,
                          mg, and 6 mg.            Whitehouse Station,
                                                   NJ 08889.
NDA 017481.............  Vermox (mebendazole)     Janssen
                          Chewable Tablets, 100    Pharmaceuticals,
                          mg.                      Inc., 1125 Trenton-
                                                   Harbourton Rd.,
                                                   Titusville, NJ 08560.
NDA 018538.............  Lozol (indapamide)       Sanofi-aventis U.S.
                          Tablets, 1.25 mg, and    LLC, 55 Corporate
                          2.5 mg.                  Dr., Bridgewater, NJ
                                                   08807.
NDA 018986.............  Pralidoxime Chloride     Meridian Medical
                          Injection (auto-         Technologies, Inc.,
                          injector), 600 mg/2      1945 Craig Rd., St.
                          milliliters (mL) (300    Louis, MO 63146.
                          mg/mL).
NDA 019999.............  Morphine Sulfate         Do.
                          Injection (auto-
                          injector), 10 mg/0.7
                          mL.
NDA 020363.............  Famvir (famciclovir)     Novartis
                          Tablets, 125 mg, 250     Pharmaceuticals
                          mg, and 500 mg.          Corp., 1 Health
                                                   Plaza, East Hanover,
                                                   NJ 07936-1080.
NDA 020711.............  Zyban (bupropion         GlaxoSmithKline LLC, 5
                          hydrochloride (HCl))     Crescent Dr.,
                          Extended-Release         Philadelphia, PA
                          Tablets, 100 mg, and     19112.
                          150 mg.
NDA 020809.............  Diclofenac Sodium        Alcon Research, LLC,
                          Ophthalmic Solution,     6201 South Freeway,
                          0.1%.                    Fort Worth, TX 76134.
NDA 021713.............  Abilify (aripiprazole)   Otsuka Pharmaceutical
                          Oral Solution, 1 mg/mL.  Co., Ltd. c/o Otsuka
                                                   Pharmaceutical
                                                   Development &
                                                   Commercialization,
                                                   Inc., 2440 Research
                                                   Blvd., Rockville, MD
                                                   20850.
NDA 021729.............  Abilify (aripiprazole)   Do.
                          Discmelt Orally
                          Disintegrating
                          Tablets, 10 mg, 15 mg,
                          20 mg, and 30 mg.
NDA 021866.............  Abilify (aripiprazole)   Do.
                          Injection, 9.75 mg/1.3
                          mL (7.5 mg/mL).
NDA 022024.............  Actoplus Met XR          Takeda Pharmaceutical
                          (metformin HCl and       U.S.A. Inc., 95
                          pioglitazone) Extended-  Hayden Ave.,
                          Release Tablets, 1gram   Lexington, MA 02421.
                          (g)/Equivalent to (EQ)
                          15 mg base and 1 g/EQ
                          30 mg base.
NDA 050605.............  Ceftin (cefuroxime       GlaxoSmithKline
                          axetil) Tablets, EQ      Intellectual Property
                          125 mg base, EQ 250 mg   (no. 2) Ltd. England,
                          base, and EQ 500 mg      c/o GlaxoSmithKline,
                          base.                    1250 South
                                                   Collegeville Rd.,
                                                   Collegeville, PA
                                                   19426.
NDA 050672.............  Ceftin (cefuroxime       Do.
                          axetil) Oral
                          Suspension, EQ 125 mg
                          base/5 mL and EQ 250
                          mg base/5 mL.
NDA 207988.............  Zurampic (lesinurad)     Ironwood
                          Tablets, 200mg.          Pharmaceuticals,
                                                   Inc., 100 Summer St.,
                                                   Suite 2300, Boston MA
                                                   02110.
NDA 208383.............  Bevyxxa (betrixaban)     Portola
                          Capsules, 40 mg and 80   Pharmaceuticals,
                          mg.                      Inc., 270 East Grand
                                                   Ave., South San
                                                   Francisco, CA 94080.
NDA 210709.............  Tekturna (aliskiren      Nodem Pharma DAC, 4820
                          hemifumarate) Capsules   Emperor Blvd.,
                          (Pellets), EQ 37.5 mg    Durham, NC 27703.
                          base.
NDA 210874.............  Qternmet XR              AstraZeneca AB, c/o
                          (dapagliflozin,          AstraZeneca
                          metformin HCl and        Pharmaceuticals LP,
                          saxagliptin) Extended-   1800 Concord Pike,
                          Release Tablets, 2.5     Wilmington, DE 19803.
                          mg/1 g/EQ 2.5 mg base,
                          5 mg/1 g/EQ 2.5 mg
                          base, 5 mg/1 g/EQ 5 mg
                          base, and 10 mg/1 g/EQ
                          5 mg base.
------------------------------------------------------------------------

    Therefore, approval of the applications listed in the table, and
all amendments and supplements thereto, is hereby withdrawn as of April
15, 2021. Approval of each entire application is withdrawn, including
any strengths and dosage forms inadvertently missing from the table.
Introduction or delivery for introduction into interstate commerce of
products without approved new drug applications violates section 301(a)
and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a)
and (d)). Drug products that are listed in the table

that are in inventory on April 15, 2021 may continue to be dispensed
until the inventories have been depleted or the drug products have
reached their expiration dates or otherwise become violative, whichever
occurs first.

    Dated: March 9, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-05368 Filed 3-15-21; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 83, Number 29 (Monday, February 12, 2018)]
[Notices]
[Pages 6069-6071]
[FR Doc No: 2018-02727]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-82644; File No. SR-ISE-2018-10]

Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing
and Immediate Effectiveness of Proposed Rule Change To Amend the
Exchange's Schedule of Fees To Modify Complex Order Fees and Rebates

February 6, 2018.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on January 30, 2018, Nasdaq ISE, LLC (``ISE'' or ``Exchange'') filed
with the Securities and Exchange Commission (``Commission'') the
proposed rule change as described in Items I and II below, which Items
have been prepared by the Exchange. The Commission is publishing this
notice to solicit comments on the proposed rule change from interested
persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend the Exchange's Schedule of Fees.
    The text of the proposed rule change is available on the Exchange's
website at http://ise.cchwallstreet.com/, at the principal office of
the Exchange, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The purpose of the proposed rule change is to amend the Exchange's
Schedule of Fees to modify certain complex order fees and rebates in
Section II, and to make a number of non-substantive changes to update
certain section headings. Each change is described below.\3\
---------------------------------------------------------------------------

    \3\ The Exchange initially filed the proposed pricing changes on
January 2, 2018 (SR-ISE-2018-02). On January 11, 2018, the Exchange
withdrew that filing and submitted SR-ISE-2018-05. On January 22,
2018, the Exchange withdrew SR-ISE-2018-05 and submitted SR-ISE-
2018-08. On January 30, 2018, the Exchange withdrew SR-ISE-2018-08
and submitted this filing.
---------------------------------------------------------------------------

Priority Customer Complex Order Rebate for Select Symbols
    Currently as set forth in Section II of the Schedule of Fees, the
Exchange provides rebates to Priority Customer \4\ complex orders that
trade with Non-Priority Customer \5\ complex orders in the complex
order book or trade with quotes and orders on the regular order book.
Rebates are tiered based on a member's average daily volume (``ADV'')
executed during a given month as follows: 0 to 14,999 contracts (``Tier
1''), 15,000 to 44,999 contracts (``Tier 2''), 45,000 to 59,999
contracts (``Tier 3''), 60,000 to 74,999 contracts (``Tier 4''), 75,000
to 99,999 contracts (``Tier 5''), 100,000 to 124,999 contracts (``Tier
6''), 125,000 to 224,999 contracts (``Tier 7''), and 225,000 or more
contracts (``Tier 8''). In Select Symbols,\6\ the rebate is $0.26 per
contract for Tier 1, $0.30 per contract for Tier 2, $0.36 per contract
for Tier 3, $0.41 per contract for Tier 4, $0.42 per contract for Tier
5, $0.44 per contract for Tier 6, $0.46 per contract for Tier 7, and
$0.49 per contract for Tier 8. The Exchange now proposes to increase
the rebate amounts to $0.45 in Tier 6 and $0.50 in Tier 8.
---------------------------------------------------------------------------

    \4\ A ``Priority Customer'' is a person or entity that is not a
broker/dealer in securities, and does not place more than 390 orders
in listed options per day on average during a calendar month for its
own beneficial account(s), as defined in ISE Rule 100(a)(37A).
    \5\ Non-Priority Customer includes Market Maker, Non-Nasdaq GEMX
Market Maker, Firm Proprietary, Broker-Dealer, and Professional
Customer.
    \6\ ``Select Symbols'' are options overlying all symbols listed
on ISE that are in the Penny Pilot Program.
---------------------------------------------------------------------------

Non-Priority Customer Complex Order Taker Fee for Select Symbols
    Currently, the Exchange charges a complex order taker fee for
Select Symbols that is $0.47 per contract for Market Maker \7\ orders
(or $0.44 per contract for Market Makers with total affiliated Priority
Customer Complex ADV of 150,000 or more contracts),\8\ and $0.48 per
contract for Non-Nasdaq ISE Market Maker,\9\ Firm Proprietary \10\/
Broker-Dealer,\11\ and Professional Customer \12\ orders. Priority
Customer orders are not charged a complex order taker fee for Select
Symbols. The Exchange now proposes to increase the complex order taker
fee to $0.50 per contract for Non-Priority Customer orders in Select
Symbols. As proposed, Market Makers with total affiliated Priority
Customer Complex ADV of

150,000 or more contracts will continue to receive the discounted fee
of $0.44. Additionally, preferenced Market Makers will continue to
receive the applicable discount of $0.02 per contract when trading
against Priority Customer order preferenced to them in the complex
order book.\13\
---------------------------------------------------------------------------

    \7\ The term ``Market Makers'' refers to ``Competitive Market
Makers'' and ``Primary Market Makers'' collectively.
    \8\ Nasdaq ISE Market Makers making or taking liquidity receive
a discount of $0.02 when trading against Priority Customer orders
preferenced to them in the Complex Order Book in equity options that
are able to be listed and traded on more than one options exchange.
This discount does not apply to FX Options Symbols or to option
classes designated by the Exchange to receive a guaranteed
allocation pursuant to Nasdaq ISE Rule 722(b)(3)(i)(B).
    \9\ A ``Non-Nasdaq ISE Market Maker'' is a market maker as
defined in Section 3(a)(38) of the Securities Exchange Act of 1934,
as amended, registered in the same options class on another options
exchange.
    \10\ A ``Firm Proprietary'' order is an order submitted by a
member for its own proprietary account.
    \11\ A ``Broker-Dealer'' order is an order submitted by a member
for a broker-dealer account that is not its own proprietary account.
    \12\ A ``Professional Customer'' is a person or entity that is
not a broker/dealer and is not a Priority Customer.
    \13\ See note 8 above.
---------------------------------------------------------------------------

Non-Priority Customer Complex Surcharge for Non-Select Symbols
    The Exchange proposes to amend Section II of the Schedule of Fees
to adopt a surcharge of $0.03 per contract on Non-Priority Customer
complex orders in Non-Select Symbols \14\ that take liquidity from the
complex order book. For clarification, the proposed Non-Priority
Customer complex surcharge will not apply to orders executed or
submitted in the Exchange's various auction mechanisms.\15\
---------------------------------------------------------------------------

    \14\ ``Non-Select Symbols'' are options overlying all symbols
excluding Select Symbols.
    \15\ Today, the complex order auctions consist of the
Facilitation Mechanism, Solicited Order Mechanism, Price Improvement
Mechanism and ``exposure'' auctions pursuant to ISE Rule
722(b)(3)(iii).
---------------------------------------------------------------------------

Update Fee Schedule Headings
    Currently, the Exchange's Schedule of Fees contains a number of
section headings that are not currently reflected in the Table of
Contents. The Exchange added or eliminated these headings as parts of
previous rule changes, and inadvertently did not make the corresponding
updates to the Table of Contents.\16\ Accordingly, the Exchange
proposes to update the Table of Contents to make its Schedule of Fees
easier to read. The Exchange also proposes to renumber Section VIII.J
to Section VIII.K in connection with these clean-up changes.
---------------------------------------------------------------------------

    \16\ In particular, the Exchange deleted Sections V.C, VI.B, and
VII.D, and added Sections V.D, VI.C, VI.E-VI.I, and VIII.J as parts
of previous rule changes to amend ISE's Schedule of Fees. See
Securities Exchange Release No. 68324 (November 30, 2012), 77 FR
72901 (December 6, 2012) (SR-ISE-2012-89); Securities Exchange
Release No. 81095 (July 7, 2017), 82 FR 32409 (July 13, 2017) (SR-
ISE-2017-62); Securities Exchange Release No. 81903 (October 19,
2017), 82 FR 49450 (October 25, 2017) (SR-ISE-2017-91); and
Securities Exchange Release No. 82446 (January 5, 2018), 83 FR 1446
(January 11, 2018) (SR-ISE-2017-112).
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that its proposal is consistent with Section
6(b) of the Act,\17\ in general, and furthers the objectives of
Sections 6(b)(4) and 6(b)(5) of the Act,\18\ in particular, in that it
provides for the equitable allocation of reasonable dues, fees, and
other charges among members and issuers and other persons using any
facility, and is not designed to permit unfair discrimination between
customers, issuers, brokers, or dealers.
---------------------------------------------------------------------------

    \17\ 15 U.S.C. 78f(b).
    \18\ 15 U.S.C. 78f(b)(4) and (5).
---------------------------------------------------------------------------

Priority Customer Complex Order Rebate for Select Symbols
    The Exchange believes that it is reasonable to increase the rebates
provided to Priority Customer complex orders in the manner discussed
above, as these proposed rebates are designed to attract additional
Priority Customer complex order volume to the Exchange. The Exchange
already provides volume-based tiered rebates for Priority Customer
complex orders, and believes that increasing the rebates will
incentivize members to send additional order flow to ISE in order to
achieve these rebates for their Priority Customer complex order volume,
creating additional liquidity to the benefit of all members that trade
complex orders on the Exchange.
    The Exchange notes that Priority Customer orders will continue to
receive complex order rebates,\19\ while other market participants will
continue to pay a fee. The Exchange does not believe that this is
unfairly discriminatory as a Priority Customer is by definition not a
broker or dealer in securities, and does not place more than 390 orders
in listed options per day on average during a calendar month for its
own beneficial account(s). This limitation does not apply to
participants whose behavior is substantially similar to that of market
professionals, including Professional Customers, who will generally
submit a higher number of orders (many of which do not result in
executions) than Priority Customers.
---------------------------------------------------------------------------

    \19\ With the exception of responses to complex crossing orders,
including complex PIM orders, where Priority Customers are charged a
fee like other market participants.
---------------------------------------------------------------------------

Non-Priority Customer Complex Order Taker Fee for Select Symbols
    The Exchange believes that it is reasonable to increase the complex
order taker fee to $0.50 per contract for Non-Priority Customer orders
in Select Symbols because the increased taker fees are designed to
offset the enhanced Priority Customer rebates discussed above.
Furthermore, the proposed taker fees are set at levels that the
Exchange believes will continue to be attractive to market participants
that trade on ISE. As noted above, Market Makers with total affiliated
Priority Customer Complex ADV of 150,000 or more contracts will
continue to receive the discounted fee of $0.44 under this proposal.
Additionally, preferenced Market Makers will continue to receive the
applicable discount of $0.02 per contract when trading against Priority
Customer order preferenced to them in the complex order book.\20\
---------------------------------------------------------------------------

    \20\ See note 8 above.
---------------------------------------------------------------------------

    The Exchange's proposal to increase the Non-Priority Customer
complex order taker fee is equitable and not unfairly discriminatory
because the increased fee will apply to all similarly-situated market
participants. As noted above, Priority Customers will continue to
receive complex order rebates, while other market participants will
continue to pay a fee. The Exchange does not believe that this is
unfairly discriminatory for the reasons discussed above. The Exchange
also notes that Market Maker orders will continue to be eligible for
lower fees than other non-Priority Customer orders. The Exchange does
not believe that it is unfairly discriminatory provide lower fees to
Market Maker orders as Market Makers are subject to additional
requirements and obligations (such as quoting requirements) that other
market participants are not.
Non-Priority Customer Complex Surcharge for Non-Select Symbols
    The Exchange believes that its proposal to adopt a surcharge of
$0.03 per contract on Non-Priority Customer complex orders in Non-
Select Symbols that take liquidity from the complex order book is
reasonable, equitable and not unfairly discriminatory. Assessing this
surcharge to only those orders that take liquidity from the market is
reasonable because the Exchange wants to continue to encourage market
participation for those participants that seek to add liquidity on ISE.
In addition, the Exchange believes that excluding complex orders
executed in the Exchange's various auction mechanisms from the proposed
Non-Priority Customer complex surcharge is reasonable for the reasons
that follow. The proposed complex surcharge will not apply to complex
orders executed in the Facilitation Mechanism, Solicited Order
Mechanism and Price Improvement Mechanism as such orders have separate
pricing in Section II of the Schedule of Fees, and the Exchange wants
to continue to encourage participation within these auction mechanisms.
The Exchange also believes that the exclusion of ``exposure'' auctions
pursuant to ISE Rule 722(b)(3)(iii) from the Non-Priority Customer
complex surcharge is reasonable because the Exchange wants to encourage
participation in this auction and have it continue to be attractive to
market participants who

will be assessed the lower fee. The Exchange believes that the complex
fee structure as proposed will remain attractive to market
participants, who will continue to be charged lower fees for adding
liquidity to the complex order book than for removing liquidity. ISE
notes that other options exchanges assess similar surcharges on complex
orders that remove liquidity from the complex order book.\21\
---------------------------------------------------------------------------

    \21\ Nasdaq PHLX (``Phlx''), CBOE Options (``CBOE''), and MIAX
Options (``MIAX'') assess similar surcharges for complex order
executions that remove liquidity from the complex order book for
non-penny classes. See Phlx Pricing Schedule, Section II, note 7;
CBOE Fees Schedule, Complex Surcharge, and note 35; and MIAX Fee
Schedule, Sections (1)(a)(i) and (ii).
---------------------------------------------------------------------------

    The Exchange's proposal to adopt the $0.03 per contract Non-
Priority Customer complex order surcharge in the manner discussed above
is equitable and not unfairly discriminatory because the surcharge will
apply to all similarly-situated market participants.
Update Fee Schedule Headings
    The Exchange believes that the clean-up changes to update the
section headings in its Schedule of Fees is reasonable, equitable and
not unfairly discriminatory because these are non-substantive changes
intended to make the Schedule of Fees more transparent to members and
investors.

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition not necessary or appropriate in
furtherance of the purposes of the Act. The proposed fees and rebates
are designed to attract additional order flow to ISE, and the Exchange
believes that its complex order pricing remains attractive to market
participants. The Exchange operates in a highly competitive market in
which market participants can readily favor competing venues if they
deem fee levels at a particular venue to be excessive, or rebate
opportunities available at other venues to be more favorable. In such
an environment, the Exchange must continually adjust its fees to remain
competitive with other exchanges. Because competitors are free to
modify their own fees in response, and because market participants may
readily adjust their order routing practices, the Exchange believes
that the degree to which fee changes in this market may impose any
burden on competition is extremely limited.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The foregoing rule change has become effective pursuant to Section
19(b)(3)(A)(ii) of the Act,\22\ and Rule 19b-4(f)(2) \23\ thereunder.
At any time within 60 days of the filing of the proposed rule change,
the Commission summarily may temporarily suspend such rule change if it
appears to the Commission that such action is: (i) Necessary or
appropriate in the public interest; (ii) for the protection of
investors; or (iii) otherwise in furtherance of the purposes of the
Act. If the Commission takes such action, the Commission shall
institute proceedings to determine whether the proposed rule should be
approved or disapproved.
---------------------------------------------------------------------------

    \22\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \23\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to [email protected]. Please include
File Number SR-ISE-2018-10 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.

All submissions should refer to File Number SR-ISE-2018-10. This file
number should be included on the subject line if email is used. To help
the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's internet website (http://www.sec.gov/rules/sro.shtml).
Copies of the submission, all subsequent amendments, all written
statements with respect to the proposed rule change that are filed with
the Commission, and all written communications relating to the proposed
rule change between the Commission and any person, other than those
that may be withheld from the public in accordance with the provisions
of 5 U.S.C. 552, will be available for website viewing and printing in
the Commission's Public Reference Room, 100 F Street NE, Washington, DC
20549, on official business days between the hours of 10:00 a.m. and
3:00 p.m. Copies of the filing also will be available for inspection
and copying at the principal office of the Exchange. All comments
received will be posted without change. Persons submitting comments are
cautioned that we do not redact or edit personal identifying
information from comment submissions. You should submit only
information that you wish to make available publicly. All submissions
should refer to File Number SR-ISE-2018-10 and should be submitted on
or before March 5, 2018.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\24\
---------------------------------------------------------------------------

    \24\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Eduardo A. Aleman,
Assistant Secretary.
[FR Doc. 2018-02727 Filed 2-9-18; 8:45 am]
 BILLING CODE 8011-01-P